title: Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice.
abstract: Pain-related functional impairment and behavioral depression are diagnostic indicators of pain and targets for its treatment. Nesting is an innate behavior in mice that may be sensitive to pain manipulations and responsive to analgesics. The goal of this study was to develop and validate a procedure for evaluation of pain-related depression of nesting in mice. Male ICR mice were individually housed and tested in their home cages. On test days, a 5- × 5-cm Nestlet was subdivided into 6 pieces, the pieces were evenly distributed on the cage floor, and Nestlet consolidation was quantified during 100-minute sessions. Baseline nesting was stable within and between subjects, and nesting was depressed by 2 commonly used inflammatory pain stimuli (intraperitoneal injection of dilute acid; intraplantar injection of complete Freund adjuvant). Pain-related depression of nesting was alleviated by drugs from 2 classes of clinically effective analgesics (the nonsteroidal anti-inflammatory drug ketoprofen and the μ-opioid receptor agonist morphine) but not by a drug from a class that has failed to yield effective analgesics (the centrally acting kappa opioid agonist U69,593). Neither ketoprofen nor morphine alleviated depression of nesting by U69,593, which suggests that ketoprofen and morphine effects were selective for pain-related depression of nesting. In contrast to ketoprofen and morphine, the kappa opioid receptor antagonist JDTic blocked depression of nesting by U69,593 but not by acid or complete Freund adjuvant. These results support utility of this procedure to assess expression and treatment of pain-related depression in mice.
authors.affiliation: Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Department of Pharmacology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan Center for Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC, USA Department of Psychological Sciences, Georgia Regents University, Augusta, GA, USA.
authors.forename: S Stevens
authors.initials: SS
authors.lastname: Negus
authors.forename: Bradley
authors.initials: B
authors.lastname: Neddenriep
authors.forename: Ahmad A
authors.initials: AA
authors.lastname: Altarifi
authors.forename: F Ivy
authors.initials: FI
authors.lastname: Carroll
authors.forename: Michael D
authors.initials: MD
authors.lastname: Leitl
authors.forename: Laurence L
authors.initials: LL
authors.lastname: Miller
mesh_terms: D000701:Analgesics, Opioid / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D044482:Benzeneacetamides / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D005620:Freund's Adjuvant / Q000633:toxicity; D007660:Ketoprofen / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009020:Morphine / Q000627:therapeutic use*; D009425:Nesting Behavior / Q000187:drug effects / Q000502:physiology*; D010146:Pain / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000494:pharmacology; D011759:Pyrrolidines / Q000627:therapeutic use; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology
chemical_list: C433814:7-hydroxy-N-(1-((4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl)methyl)-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide; D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D044482:Benzeneacetamides; D010880:Piperidines; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D044005:Tetrahydroisoquinolines; D009020:Morphine; D005620:Freund's Adjuvant; D007660:Ketoprofen; C045444:U 69593
references.citation: Methods Mol Biol. 2010;617:79-91
references.pmid: 20336415
references.citation: Prog Neurobiol. 2009 Jul;88(3):184-202
references.pmid: 19393288
references.citation: J Med Chem. 2013 Mar 28;56(6):2178-95
references.pmid: 23360448
references.citation: J Am Assoc Lab Anim Sci. 2014 Jan;53(1):24-8
references.pmid: 24411776
references.citation: Neurosci Lett. 2013 Dec 17;557 Pt A:65-72
references.pmid: 23994390
references.citation: Psychopharmacology (Berl). 1994 Jul;115(3):311-9
references.pmid: 7871070
references.citation: Eur J Pain. 2012 Apr;16(4):485-95
references.pmid: 22396078
references.citation: Br J Pharmacol. 2014 Jun;171(12):2951-63
references.pmid: 24527763
references.citation: Pain. 2012 Apr;153(4):876-884
references.pmid: 22341563
references.citation: Lab Anim (NY). 2013 Aug;42(8):292-300
references.pmid: 23877610
references.citation: Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9
references.pmid: 15464069
references.citation: Pain. 1999 Mar;80(1-2):67-82
references.pmid: 10204719
references.citation: J Vis Exp. 2013 Dec 24;(82):51012
references.pmid: 24429701
references.citation: Curr Neuropharmacol. 2013 Dec;11(6):560-91
references.pmid: 24396334
references.citation: Pain. 1998 Mar;75(1):129-140
references.pmid: 9539682
references.citation: Psychopharmacology (Berl). 2010 Jun;210(2):149-59
references.pmid: 20101391
references.citation: Pain. 1995 May;61(2):325-343
references.pmid: 7659444
references.citation: Front Behav Neurosci. 2010 Oct 12;4:165
references.pmid: 21031028
references.citation: Eur J Pain. 2014 Feb;18(2):204-12
references.pmid: 23853119
references.citation: Mol Pain. 2014 Sep 23;10:62
references.pmid: 25245060
references.citation: CNS Drug Rev. 2003 Summer;9(2):187-98
references.pmid: 12847558
references.citation: Science. 1946 Jun 7;103(2684):677-80
references.pmid: 20984256
references.citation: Front Pharmacol. 2014 Nov 17;5:253
references.pmid: 25452729
references.citation: Behav Genet. 1973 Sep;3(3):247-56
references.pmid: 4750243
references.citation: Nat Methods. 2014 Jun;11(6):629-32
references.pmid: 24776635
references.citation: Neuropsychopharmacology. 2014 Feb;39(3):614-24
references.pmid: 24008352
references.citation: J Pharmacol Exp Ther. 2006 Nov;319(2):507-14
references.pmid: 16751251
references.citation: Pain. 2005 Jan;113(1-2):9-19
references.pmid: 15621359
references.citation: J Pharmacol Exp Ther. 2007 Jan;320(1):194-201
references.pmid: 17050782
references.citation: Pain. 2008 Aug 31;138(2):423-439
references.pmid: 18355964
references.citation: Clin Neuropharmacol. 1996 Oct;19(5):451-6
references.pmid: 8889289
references.citation: J Pain. 2014 Feb;15(2):121-8
references.pmid: 24287315
references.citation: Nat Protoc. 2006;1(3):1117-9
references.pmid: 17406392
references.citation: Ann Acad Med Singap. 1994 Mar;23(2):129-38
references.pmid: 8080219
references.citation: J Pharmacol Exp Ther. 2012 Nov;343(2):389-400
references.pmid: 22892341
references.citation: Life Sci. 2009 Aug 12;85(7-8):309-15
references.pmid: 19559034
references.citation: J Neurosci Methods. 2014 Aug 30;234:139-46
references.pmid: 24525328
references.citation: Curr Biol. 2015 Feb 2;25(3):326-332
references.pmid: 25601547
references.citation: Clin Neuropharmacol. 1996 Feb;19(1):92-7
references.pmid: 8867523
references.citation: Psychopharmacology (Berl). 2011 Jun;215(3):455-65
references.pmid: 21373789
references.citation: Anesthesiology. 2004 Jul;101(1):191-203
references.pmid: 15220791
references.citation: J Pain. 2006 Jun;7(6):408-16
references.pmid: 16750797
references.citation: J Am Assoc Lab Anim Sci. 2013;52(3):228-32
references.pmid: 23849403